Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab vs Steroids and Cyclophosphamide in Idiopathic Membranous Nephropathy
NCT03018535Phase 3Unknown
- Sponsor
- ASST Spedali Civili di Brescia
- Start
- Jan 2012
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab in idiopathic membranous nephropathy (IMN) (2 arms), sponsored by ASST Spedali Civili di Brescia. Primary endpoint: Probability of Complete Remission at 1 year. Status: unknown.
02
Drugs
rituximab
03
Conditions
idiopathic membranous nephropathy (IMN)
Beyond the preview
Go deeper on NCT03018535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03018535.